Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Multiple Myeloma 427Neoplasms, Plasma Cell 68Lymphoma, Mantle-Cell 66Lymphoma 65Recurrence 64Lymphoma, Non-Hodgkin 43Lymphoma, Follicular 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Leukemia, Myeloid, Acute 36Lymphoma, Large B-Cell, Diffuse 34Waldenstrom Macroglobulinemia 33Lymphoma, B-Cell, Marginal Zone 30Leukemia, Lymphocytic, Chronic, B-Cell 28Neoplasms 24Carcinoma, Non-Small-Cell Lung 24Immunoglobulin Light-chain Amyloidosis 23Leukemia 21Hodgkin Disease 17Lymphoma, B-Cell 14Burkitt Lymphoma 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Myelodysplastic Syndromes 13Lymphoma, Large-Cell, Anaplastic 13Hematologic Neoplasms 13Immunoblastic Lymphadenopathy 12Breast Neoplasms 12Mycosis Fungoides 11Lymphoma, T-Cell, Cutaneous 11Lymphoma, Large-Cell, Immunoblastic 11Congenital Abnormalities 11

Interventions

Pemetrexed 14Carboplatin 13osimertinib 10aflutinib 9Drug Therapy 9Gefitinib 7Radiotherapy 6Docetaxel 6Cisplatin 6anlotinib 5Radiosurgery 5Paclitaxel 5pembrolizumab 4Vinorelbine 4Gemcitabine 4tislelizumab 3icotinib 3apatinib 3HM781-36B 3Erlotinib Hydrochloride 3toripalimab 2spartalizumab 2rezivertinib 2camrelizumab 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2Immune Checkpoint Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × NSCLC × Bortezomib × Clear all
NCT00283634 2011-02-17

A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

Millennium Pharmaceuticals, Inc.

Phase 2 Terminated
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡